arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Prelude Therapeutics Inc

PRLD

$3.55 ▼ -0.55 (-13.41%) at close

8 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Prelude Therapeutics Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $273.2M

Dividend Yield —

Revenue Growth 73.4%

Op. Margin —

ROIC -120.4% ↘

FCF / Share $-0.73 ↗

Trailing P/E —

Price / Book 4.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$12.14M

↑ +73.4% —

Net Income Profit after all expenses

$-99.50M

↑ +21.8% —

FCF / Share Free cash flow per share

$-0.73

↑ +46.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	73.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+818%)	—	—	—	—	—	—	—
EPS Growth YoY (%)	23.2% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	16.8% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	17.2% Good Good Year-over-year change in earnings per share Optimal: > 10%	-0.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	21.8% Good ↑ Good Improving Year-over-year change in net income	-4.4% Weak ↑ Weak Improving Year-over-year change in net income	-5.5% Weak ↑ Weak Improving Year-over-year change in net income	-3.4% Weak ↑ Weak Improving Year-over-year change in net income	-96.2% Weak Weak Year-over-year change in net income	-106.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	46.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	25.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-0.0% Weak Weak Year-over-year change in free cash flow	1.8% Caution Caution Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
FCF Margin (%) (%)	-464.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—
FCF / Net Income (x)	0.57x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-120.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-84.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-49.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	44.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-74.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-79.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-56.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-26.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-128.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-145.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1066%)	-96.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-745%)	-51.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-443%)	-59.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-494%)	-39.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-360%)	-26.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-279%)	55.8% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+272%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-35.26M	$-12.47M	$-25.29M	$-30.61M	$-31.83M	$-218.31M	$-18.88M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.16	$0.09	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.29	$-1.68	$-2.02	$-2.44	$-2.43	—	—	—
Free Cash Flow per Share (USD)	$-0.73	$-1.37	$-1.83	$-1.83	$-1.86	—	—	—
Book Value per Share (USD)	$0.89	$1.73	$3.93	$4.13	$6.21	—	—	—
Tangible Book Value per Share (USD)	$0.89	$1.73	$3.93	$4.13	$6.21	—	—	—
Basic Weighted Avg Shares (shares)	76.96M	75.81M	60.36M	47.37M	46.05M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$52.70M	$110.25M	$213.76M	$182.68M	$275.91M	$209.43M	$15.39M	—
Total Equity (USD)	$68.64M	$131.46M	$237.09M	$195.44M	$285.90M	$212.18M	$-49.41M	$-22.69M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$12.14M	$7.00M	—	—	—	—	—	—
Depreciation Expense (USD)	$1.71M	$1.77M	$1.17M	$1.32M	$915.00K	$542.00K	$382.00K	—
Net Income, GAAP (USD)	$-99.50M	$-127.17M	$-121.83M	$-115.44M	$-111.69M	$-56.93M	$-27.57M	—
Operating Cash Flow (USD)	$-56.30M	$-102.89M	$-107.06M	$-83.73M	$-83.53M	$-46.18M	$-25.66M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 31 quarters

Prelude Therapeutics Inc

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PRLD with peers